About Anterios
Anterios is a Healthcare company based in New York (United States) founded in 2006 by Robert Nicolosi and Jonathan T Edelson, and was acquired by Allergan in January 2016. Botulinum-based products for dermatology and aesthetics are developed. Anterios has raised $26.9 million across 7 funding rounds from investors including Allergan, Ascent Biomedical Ventures and DRW Trading Group. Its chief executive, as recorded, is Jonathan T Edelson. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its legal entity is Anterios Inc. Its competitors include Avidity Biosciences, Revance Therapeutics and Sutro Biopharma; 3 of its 3 listed competitors have raised funding.
Company details
Anterios was a clinical stage company developing novel delivery technologies and formulations for neurotoxins through skin. Anterios NDS proprietary platform delivery technology enables local, targeted delivery of neurotoxins through the skin without the need for injections. NDS also enables the formulation of macromolecules as ready-to-use liquid injectable products. Its lead drug ANT-1207 is a topical formulation of botulinum toxin type A for the potential treatment of hyperhidrosis (excessive sweating), acne, and crows feet lines. The company has completed a pair of Phase II studies in acne, crows feet lines and Hyperhidrosis, according to ClinicalTrials.gov. The company was acquired by Allergan in Jan 2016, before which it spun out its other assets, including an injectable botulinum, into a new firm called Eirion Therapeutics.
Apps and channels of Anterios
its YouTube channel AbbVie has 56 subscribers and 30 videos.
Videos from Anterios
The most watched videos on Anterios's YouTube channel, AbbVie (56 subscribers). Click a video to play it here.
More on AbbVie.
Funding Insights of Anterios
Anterios has successfully raised a total of $26.9M across 7 strategic funding rounds. The most recent funding activity was a Series A round of $8.5 million completed in April 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $26.9M
- Total Rounds 7
- Last Round Series A β $8.5M
- First Round $5.95M
(Jun 2007)
- Investors Count 6
All 7 funding rounds of Anterios with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2013 | $8.5M | Series A | β | Ascent Biomedical Ventures, DRW Trading Group | β |
| Jul 2011 | $3.04M | Series A | β | β | β |
| Dec 2010 | $2M | Series A | β | β | β |
| Sep 2010 | $750,000 | Series A | β | β | β |
| Feb 2010 | $1.5M | Series A | β | β | β |
| Oct 2009 | $5.17M | Series A | β | β | β |
| Jun 2007 | $5.95M | Series A | β | β | β |
7 investors in total: 7 institutional.
Investors in Anterios
Anterios has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Allergan, Ascent Biomedical Ventures and DRW Trading Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| abvlp.com | ||||
| quantumtp.com | ||||
A venture capital firm focused on early-stage MedTech investments. | 2006 | shdpartners.com | Dallas, United States | |
A single-family office with diverse investment portfolios is operated. | 2002 | spring-bay.com | Ponte Vedra Beach, United States | |
Diversified trading firm providing liquidity and technology solutions in finance. | 1992 | drw.com | Chicago, United States | |
Functions as a hedge fund focused on investment strategies. | 1999 | praesideo.com | Ogden, United States | |
A portfolio of generic medicines is developed and manufactured. | 1948 | allergan.com | Madison, United States |
Investor details for Anterios
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Anterios
2 people are tracked at Anterios (2 in leadership).
| Name | Role | Group |
|---|---|---|
Robert Nicolosi | Co-Founder | Leadership |
Jonathan T Edelson | Co-Founder & CEO | Leadership |
Complete people profiles for Anterios
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Anterios
4 dated milestones of Anterios across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Anterios is founded.
- Funding First funding round of $6.0M.
- Funding Latest funding round, Series A, of $8.5M.
- Exit Acquired by Allergan.
Competitors of Anterios
Anterios has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Revance Therapeutics and Sutro Biopharma.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| revance.com | 2002 | Newark, United States | $154.56M | 597 | Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. |
Detailed competitors of Anterios
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Anterios (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Anterios
Complete news archive for Anterios
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Anterios
Anterios was founded in 2006 and raised its 1st funding round 1 year after it was founded.
Anterios is headquartered in New York, United States. It is registered at New York, New York, United States.
Jonathan T Edelson is the CEO of Anterios, as recorded in our data. They have also founded this company.
Anterios is a funded company, having raised a total of $26.9M across 7 funding rounds to date. The company's 1st funding round was a Series A of $5.95M, raised on Jun 2007.
Anterios was a clinical stage company developing novel delivery technologies and formulations for neurotoxins through skin. Anterios NDS proprietary platform delivery technology enables local, targeted delivery of neurotoxins through the skin without the need for injections. NDS also enables the formulation of macromolecules as ready-to-use liquid injectable products. Its lead drug ANT-1207 is a topical formulation of botulinum toxin type A for the potential treatment of hyperhidrosis (excessive sweating), acne, and crows feet lines. The company has completed a pair of Phase II studies in acne, crows feet lines and Hyperhidrosis, according to ClinicalTrials.gov. The company was acquired by Allergan in Jan 2016, before which it spun out its other assets, including an injectable botulinum, into a new firm called Eirion Therapeutics.
Anterios's top competitors include Revance Therapeutics, Sutro Biopharma and Avidity Biosciences.
Anterios has 7 investors. Key investors include Allergan, Ascent Biomedical Ventures, DRW Trading Group, Praesideo Management, and Quantum Technology Partners.
Anterios operates through Anterios Inc.
Yes. Anterios was acquired by Allergan in January 2016.

